Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Sep;53(9):3650-6.
doi: 10.1128/AAC.00174-09. Epub 2009 Jun 15.

Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis

Dominique Hubert  1 , Evelyne Le Roux, Thibaud Lavrut, Benoit Wallaert, Philippe Scheid, Dominique Manach, Dominique Grenet, Isabelle Sermet-Gaudelus, Sophie Ramel, Claire Cracowski, Anne Sardet, Nathalie Wizla, Eric Deneuville, Rodolphe Garraffo
Affiliations
Randomized Controlled Trial

Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis

Dominique Hubert et al. Antimicrob Agents Chemother. 2009 Sep.

Abstract

The present multicenter, randomized crossover study compared the safety and efficacy of continuous infusion with those of short infusions of ceftazidime in patients with cystic fibrosis. Patients with chronic Pseudomonas aeruginosa colonization received two successive courses of intravenous tobramycin and ceftazidime (200 mg/kg of body weight/day) for pulmonary exacerbation administered as thrice-daily short infusions or as a continuous infusion. The primary endpoint was the variation in the forced expiratory volume in 1 s (FEV1) during the course of antibiotic treatment. Sixty-nine of the 70 patients enrolled in the study received at least one course of antibiotic treatment. The improvement in FEV1 at the end of therapy was not statistically different between the two treatment procedures (+7.6% after continuous infusion and +5.5% after short infusions) but was better after continuous ceftazidime treatment in patients harboring resistant isolates (P < 0.05). The interval between the course of antibiotic treatments was longer after the continuous infusion than after the short infusion of ceftazidime (P = 0.04). The mean serum ceftazidime concentration during the continuous infusion was 56.2 +/- 23.2 microg/ml; the mean peak and trough concentrations during the short infusions were 216.3 +/- 71.5 and 12.1 +/- 8.7 microg/ml, respectively. The susceptibility profiles of the P. aeruginosa isolates remained unchanged and were similar for both regimens. Quality-of-life scores were similar whatever the treatment procedure, but 82% of the patients preferred the continuous-infusion regimen. Adverse events were not significantly different between the two regimens. In conclusion, the continuous infusion of ceftazidime did not increase its toxicity and appeared to be as efficient as short infusions in patients with cystic fibrosis as a whole, but it gave better results in patients harboring resistant isolates of P. aeruginosa.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Flowchart of study performance.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alou, L., L. Aguilar, D. Sevillano, M. J. Giménez, O. Echeverría, M. L. Gómez-Lus, and J. Prieto. 2005. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J. Antimicrob. Chemother. 55:209-213. - PubMed
    1. Baririan, N., H. Chanteux, E. Viaene, H. Servais, and P. M. Tulkens. 2003. Stability and comparability study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J. Antimicrob. Chemother. 51:651-658. - PubMed
    1. Benko, A. S., D. M. Cappelletty, J. A. Kruse, and M. J. Rybak. 1996. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob. Agents Chemother. 40:691-695. - PMC - PubMed
    1. Bosso, J. A., C. R. Bonapac, P. A. Flume, and R. L. White. 1999. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy 19:620-626. - PubMed
    1. Byl, B., D. Baran, F. Jacobs, A. Herschuelz, and J. P. Thys. 2001. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients. J. Antimicrob. Chemother. 48:325-327. - PubMed

Publication types